liu.seSearch for publications in DiVA
Endre søk
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer
Sahlgrenska Cancer Center, University of Gothenburg, Sweden.
Sahlgrenska Cancer Center, University of Gothenburg, Sweden.
Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden .
Sahlgrenska Cancer Center, University of Gothenburg, Sweden.
Vise andre og tillknytning
2013 (engelsk)Inngår i: BMC Cancer, ISSN 1471-2407, E-ISSN 1471-2407, Vol. 13, nr 47Artikkel i tidsskrift (Fagfellevurdert) Published
Abstract [en]

Background

Previously, we performed analysis of gene expression in 46 axillary lymph node negative tumors and identified molecular gene signatures that resulted in different clinical outcomes. The aim of this study was to determine the correlation of γ-glutamyl hydrolase (GGH), fatty acid amide hydrolase (FAAH), Pirin (PIR) and TAF5-like RNA polymerase II, p300/CBP-associated factor (PCAF)-associated factor, 65 kDa (TAF5L), selected from identified gene signatures, with clinical outcomes as well as classical clinicopathological characteristics in primary invasive breast cancer patients.

Methods

The protein levels of GGH, FAAH, PIR and TAF5L were assessed by immunohistochemistry (IHC) on a panel of 80 primary invasive breast tumors. Quantitative real-time PCR (qRT-PCR) and western blot analysis were performed to verify the expression levels of the candidate biomarkers. Patient disease-specific survival (DSS) and recurrence-free survival (RFS) were evaluated using the Kaplan-Meier method. The prognostic biomarkers were identified by univariate analysis with a log-rank test and by multivariate analysis with Cox proportional hazards regression models.

Results

The GGH and FAAH protein levels were significantly up-regulated in invasive breast cancer tumors compared with adjacent non-cancerous tissues. Furthermore, the protein levels of GGH and FAAH were significantly correlated in tumor tissues. Tumoral GGH protein expression was significantly correlated with shorter DSS and RFS. Furthermore, the protein expression of GGH was positively correlated with undifferentiated tumors (BRE grade III) and ER/PR expressing tumors. Multivariate regression analysis showed that only GGH protein expression independently predicts DSS. No such correlations were found for FAAH, PIR and TAF5L protein expression. However, elevated protein levels of FAAH were positively associated with high number of lymph node involvement and upregulated levels of PIR were positively related with lymph node metastasis. The TAF5L was pronouncedly down-regulated in primary invasive breast cancer tissues compared to matched adjacent non-cancerous tissues.

Conclusion

These data show for the first time that cytoplasmic GGH might play a relevant role in the development and progression of invasive breast cancer, warranting further investigations. Our findings suggest that GGH serve as a potential biomarker of unfavorable clinical outcomes over short-term follow-up in breast cancer. The GGH may be a very attractive targeted therapy for selected patients.

sted, utgiver, år, opplag, sider
BioMed Central, 2013. Vol. 13, nr 47
Emneord [en]
GGH, Breast cancer, Primary invasive breast cancer tumors, Prognostic factor, Disease specific survival, Recurrence-free survival
HSV kategori
Identifikatorer
URN: urn:nbn:se:liu:diva-90100DOI: 10.1186/1471-2407-13-47ISI: 000315027800001PubMedID: 23374458OAI: oai:DiVA.org:liu-90100DiVA, id: diva2:612057
Tilgjengelig fra: 2013-03-19 Laget: 2013-03-19 Sist oppdatert: 2017-12-06bibliografisk kontrollert

Open Access i DiVA

fulltext(1749 kB)314 nedlastinger
Filinformasjon
Fil FULLTEXT01.pdfFilstørrelse 1749 kBChecksum SHA-512
01be6edd21af7ba9bc97763bad356c2283eaa44e944f48f8457793794a2f06ec22f345dffbb96299ce6929580504d64f043edb9fefe622111a6ddd00e06ae777
Type fulltextMimetype application/pdf

Andre lenker

Forlagets fulltekstPubMed

Personposter BETA

Enerbäck, Charlotta

Søk i DiVA

Av forfatter/redaktør
Enerbäck, Charlotta
Av organisasjonen
I samme tidsskrift
BMC Cancer

Søk utenfor DiVA

GoogleGoogle Scholar
Totalt: 314 nedlastinger
Antall nedlastinger er summen av alle nedlastinger av alle fulltekster. Det kan for eksempel være tidligere versjoner som er ikke lenger tilgjengelige

doi
pubmed
urn-nbn

Altmetric

doi
pubmed
urn-nbn
Totalt: 182 treff
RefereraExporteraLink to record
Permanent link

Direct link
Referera
Referensformat
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annet format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annet språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf